Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer

BACKGROUND: Previously we demonstrated that the resection of primary 4T1 tumors only slightly prolongs mouse survival, but importantly, creates a “window of opportunity” with attenuated suppressor cell and increased activated T cell populations. This suggests that additional activation of the immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghochikyan, Anahit, Pichugin, Alexey, Bagaev, Alexander, Davtyan, Arpine, Hovakimyan, Armine, Tukhvatulin, Amir, Davtyan, Hayk, Shcheblyakov, Dmitry, Logunov, Denis, Chulkina, Marina, Savilova, Anastasia, Trofimov, Dmitry, Nelson, Edward L, Agadjanyan, Michael G, Ataullakhanov, Ravshan I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261251/
https://www.ncbi.nlm.nih.gov/pubmed/25432242
http://dx.doi.org/10.1186/s12967-014-0322-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261251/
https://www.ncbi.nlm.nih.gov/pubmed/25432242
http://dx.doi.org/10.1186/s12967-014-0322-y

Ejemplares similares